Ladas S D, Tassios P S, Raptis S A
Second Department of Internal Medicine, Evangelismos Hospital, Athens University, Greece.
Am J Gastroenterol. 2000 Feb;95(2):374-80. doi: 10.1111/j.1572-0241.2000.t01-1-01756.x.
Treating patients with erosive esophagitis and maintaining remission in a cost-effective fashion is a desirable goal in clinical practice. There are no established criteria to identify patients with healed esophagitis who will subsequently remain in remission with low-dose omeprazole therapy. We investigated whether 24-h esophageal-gastric pH monitoring could provide criteria to select patients for low-dose omeprazole maintenance therapy.
Seventy consecutive symptomatic outpatients with grade 2-3 reflux esophagitis were prospectively investigated. They were treated with 20 mg/day omeprazole for 2 months. Those with healed esophagitis were given alternate-evening 20-mg omeprazole maintenance therapy for 6 months. Clinical evaluation, endoscopy, and 24-h esophageal-gastric pH were done at the end of each treatment period. Results of pH studies of patients in remission were compared with those with endoscopically documented relapse of esophagitis.
In 63/70 patient (intention-to-treat, 90%; 95% confidence interval [CI], 83-97%) esophagitis was healed at 2 months. During the 6-month maintenance period esophagitis remain healed in 28 (G1) (40%; 95% CI, 29-52%), but recurred in 32 patients (G2). During healing with omeprazole 20 mg/day the 24-h gastric pH was below 4 for <10% of the time in 96% of the patients, who subsequently remained in long-term remission with low-dose maintenance therapy (G1), but not in any patient with recurrence of esophagitis (G2). The 10% threshold value has a specificity of 1.00 and sensitivity of 0.96.
The 24-h intragastric pH monitoring during 20 mg/day omeprazole therapy provides criteria by which to preselect patients with reflux esophagitis who will remain in remission with low-dose omeprazole therapy.
以具有成本效益的方式治疗糜烂性食管炎患者并维持缓解是临床实践中一个理想的目标。目前尚无既定标准来识别食管炎已愈合且随后采用低剂量奥美拉唑治疗仍能维持缓解的患者。我们研究了24小时食管-胃pH监测是否能为选择低剂量奥美拉唑维持治疗的患者提供标准。
对70例连续的有症状的2-3级反流性食管炎门诊患者进行前瞻性研究。他们接受20毫克/天的奥美拉唑治疗2个月。食管炎已愈合的患者接受隔日20毫克奥美拉唑维持治疗6个月。在每个治疗期结束时进行临床评估、内镜检查和24小时食管-胃pH监测。将缓解患者的pH研究结果与内镜记录有食管炎复发的患者的结果进行比较。
63/70例患者(意向性治疗,90%;95%置信区间[CI],83-97%)在2个月时食管炎愈合。在6个月的维持期内,28例(G1组)(40%;95%CI,29-52%)食管炎仍愈合,但32例患者(G2组)复发。在使用20毫克/天奥美拉唑愈合期间,96%的患者24小时胃pH低于4的时间<10%,这些患者随后采用低剂量维持治疗长期缓解(G1组),但食管炎复发的任何患者(G2组)均未出现这种情况。10%的阈值特异性为1.00,敏感性为0.96。
在20毫克/天奥美拉唑治疗期间的24小时胃内pH监测提供了一种标准,可据此预先选择反流性食管炎患者,这些患者采用低剂量奥美拉唑治疗仍能维持缓解。